AR108845A1 - DERIVATIVES OF [1,2,3] TRIAZOLO [4,5-D] PYRIMIDINE AS MODULATORS OF THE CB2 RECEIVER - Google Patents
DERIVATIVES OF [1,2,3] TRIAZOLO [4,5-D] PYRIMIDINE AS MODULATORS OF THE CB2 RECEIVERInfo
- Publication number
- AR108845A1 AR108845A1 ARP170101708A ARP170101708A AR108845A1 AR 108845 A1 AR108845 A1 AR 108845A1 AR P170101708 A ARP170101708 A AR P170101708A AR P170101708 A ARP170101708 A AR P170101708A AR 108845 A1 AR108845 A1 AR 108845A1
- Authority
- AR
- Argentina
- Prior art keywords
- triazolo
- pyrimidine
- derivatives
- azido
- isothiocyanate
- Prior art date
Links
- GIIGHSIIKVOWKZ-UHFFFAOYSA-N 2h-triazolo[4,5-d]pyrimidine Chemical class N1=CN=CC2=NNN=C21 GIIGHSIIKVOWKZ-UHFFFAOYSA-N 0.000 title abstract 2
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 abstract 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000107 disulfanyl group Chemical group [*]SS[H] 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 150000002540 isothiocyanates Chemical class 0.000 abstract 1
- PFBSKKDDNYQKQR-UHFFFAOYSA-N n-azido-1-sulfanylidenemethanimine Chemical compound [N-]=[N+]=NN=C=S PFBSKKDDNYQKQR-UHFFFAOYSA-N 0.000 abstract 1
- 125000001715 oxadiazolyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical group [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 125000005190 thiohydroxy group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
Abstract
La presente solicitud se refiere a derivados de [1,2,3]triazolo[4,5-d]pirimidina como moduladores del receptor CB2, útiles en el tratamiento del dolor, trastornos inmunológicos, insuficiencia cardíaca, etc. Reivindicación 1: Compuesto de fórmula (1), en las que: R¹ es un anillo seleccionado de entre fenilo y [1,2,5]oxadiazolilo, en el que dicho anillo se sustituye con un sustituyente seleccionado de entre halosulfonilo, halosulfonilalquilo, isotiocianatoalquilo, isotiocianato, aminoalquildisulfanilalquilo, hidroxialquildisulfanilalquilo, hidroxialquildisulfanilo, aminoalquildisulfanilo, halógeno, alquilo, piridinildislfanilalquilo, benzotriazolilsulfonilalquilo, dihidroxialquildisulfanilalquilo y piridinildisulfanilo y opcionalmente sustituido adicionalmente con ciano; R² y R³ se seleccionan independientemente de entre hidrógeno, hidroxilo, halógeno, tiohidroxilo, tiohidroxiazetidinilo, azido, isotiocianato y alquildisulfanilo, con la condición de que por lo menos uno de entre R¹, R² y R³ sea un grupo que comprende sulfonilo, isotiocianato, disulfanilo, tiohidroxilo o azido; R⁴ es alquilo o fenilhaloalquilo; y n es 0 ó 1; o una sal o éster farmacéuticamente aceptable del mismo.The present application refers to derivatives of [1,2,3] triazolo [4,5-d] pyrimidine as CB2 receptor modulators, useful in the treatment of pain, immunological disorders, heart failure, etc. Claim 1: Compound of formula (1), wherein: R¹ is a ring selected from phenyl and [1,2,5] oxadiazolyl, wherein said ring is substituted with a substituent selected from halosulfonyl, halosulfonylalkyl, isothiocyanatoalkyl ; R² and R³ are independently selected from hydrogen, hydroxy, halogen, thiohydroxyl, thiohydroxyazetidinyl, azido, isothiocyanate and alkyldisulfanyl, with the proviso that at least one of R², R² and R³ is a group comprising sulfonyl, isothiocyanate, disulfanyl , thiohydroxy or azido; R⁴ is alkyl or phenylhaloalkyl; and n is 0 or 1; or a pharmaceutically acceptable salt or ester thereof.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16175924 | 2016-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR108845A1 true AR108845A1 (en) | 2018-10-03 |
Family
ID=56203225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170101708A AR108845A1 (en) | 2016-06-23 | 2017-06-21 | DERIVATIVES OF [1,2,3] TRIAZOLO [4,5-D] PYRIMIDINE AS MODULATORS OF THE CB2 RECEIVER |
Country Status (24)
Country | Link |
---|---|
US (1) | US10457685B2 (en) |
EP (2) | EP4108665A1 (en) |
JP (2) | JP6962942B2 (en) |
KR (2) | KR20230062680A (en) |
CN (4) | CN109348716A (en) |
AR (1) | AR108845A1 (en) |
AU (2) | AU2017283136C1 (en) |
BR (1) | BR112018075143A2 (en) |
CA (2) | CA3206921A1 (en) |
CL (1) | CL2018003610A1 (en) |
CO (1) | CO2018011231A2 (en) |
CR (2) | CR20180615A (en) |
IL (2) | IL262711B2 (en) |
MA (1) | MA45442A (en) |
MX (1) | MX2018014684A (en) |
MY (1) | MY197244A (en) |
PE (1) | PE20190109A1 (en) |
PH (1) | PH12018502733A1 (en) |
RU (1) | RU2741597C2 (en) |
SG (2) | SG10202113286RA (en) |
TW (2) | TWI764908B (en) |
UA (1) | UA123834C2 (en) |
WO (1) | WO2017220517A1 (en) |
ZA (1) | ZA201807133B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3475280B1 (en) | 2016-06-23 | 2020-04-08 | H. Hoffnabb-La Roche Ag | Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives |
WO2017220544A1 (en) | 2016-06-23 | 2017-12-28 | F. Hoffmann-La Roche Ag | Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives |
CN109311886B (en) | 2016-06-23 | 2021-11-09 | 豪夫迈·罗氏有限公司 | [1,2,3] triazolo [4,5-d ] pyrimidine derivatives |
CN113387845B (en) * | 2021-07-16 | 2022-12-20 | 国药集团化学试剂有限公司 | Preparation method of phenylmethylsulfonyl fluoride |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001028557A1 (en) * | 1999-10-18 | 2001-04-26 | University Of Connecticut | Cannabimimetic indole derivatives |
RU2007122351A (en) * | 2004-11-15 | 2008-12-20 | Тайсо Фармасьютикал Ко. | IMINE COMPOUND |
AU2006230292A1 (en) | 2005-03-31 | 2006-10-05 | Schering Corporation | Spirocyclic thrombin receptor antagonists |
FR2887550A1 (en) | 2005-06-24 | 2006-12-29 | Sanofi Aventis Sa | New 1-benzylpyrazole-3-acetamide compounds are cannabinoids receptor antagonists useful to treat/prevent immune disorders, pain, gastrointestinal disturbances, cardiovascular/kidney disorders and in cancer chemotherapy |
CN101454327A (en) * | 2006-03-30 | 2009-06-10 | Irm责任有限公司 | Azolopyrimidines as inhibitors of cannabinoid 1 activity |
US8629157B2 (en) * | 2009-01-05 | 2014-01-14 | Boehringer Ingelheim International Gmbh | Pyrrolidine compounds which modulate the CB2 receptor |
EP2311443A1 (en) | 2009-10-15 | 2011-04-20 | Rheinische Friedrich-Wilhelms-Universität | Pharmaceutical composition containing cannabinoid-receptor 2 antagonists |
CN102924457A (en) * | 2011-08-12 | 2013-02-13 | 上海恒瑞医药有限公司 | Triazolopyrimidine derivatives, preparation method and uses thereof |
UA111640C2 (en) * | 2011-11-08 | 2016-05-25 | Ф. Хоффманн-Ля Рош Аг | DERIVATIVES [1,2,3] TRIAZOLO [4,5-d] PYRIMIDINE AS A cannabinoid receptor agonist 2 |
US9067943B2 (en) * | 2011-11-25 | 2015-06-30 | Hoffmann-La Roche Inc. | [1,2,3]triazolo[4,5-D]pyrimidine derivatives |
EA027935B1 (en) | 2013-03-07 | 2017-09-29 | Ф. Хоффманн-Ля Рош Аг | Novel pyrazol derivatives |
DK2991988T3 (en) | 2013-05-02 | 2017-08-21 | Hoffmann La Roche | Pyrrolo [2,3-d] pyrimidine derivatives as CB2 receptor agonists |
AU2014261585B2 (en) * | 2013-05-02 | 2018-03-08 | F. Hoffmann-La Roche Ag | Purine derivatives as CB2 receptor agonists |
HUE055201T2 (en) * | 2013-09-06 | 2021-11-29 | Hoffmann La Roche | Triazolo[4,5-d]pyrimidine derivatives as cb2 receptor antagonists |
EP3215506B1 (en) | 2014-11-07 | 2019-01-02 | F.Hoffmann-La Roche Ag | Triazolo[4,5-d]pyrimidines as agonists of the cannabinoid receptor 2 |
WO2017220544A1 (en) | 2016-06-23 | 2017-12-28 | F. Hoffmann-La Roche Ag | Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives |
CN109311886B (en) | 2016-06-23 | 2021-11-09 | 豪夫迈·罗氏有限公司 | [1,2,3] triazolo [4,5-d ] pyrimidine derivatives |
EP3475280B1 (en) | 2016-06-23 | 2020-04-08 | H. Hoffnabb-La Roche Ag | Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives |
-
2017
- 2017-06-20 MY MYPI2018002797A patent/MY197244A/en unknown
- 2017-06-20 UA UAA201900294A patent/UA123834C2/en unknown
- 2017-06-20 CN CN201780036295.XA patent/CN109348716A/en active Pending
- 2017-06-20 SG SG10202113286RA patent/SG10202113286RA/en unknown
- 2017-06-20 WO PCT/EP2017/064994 patent/WO2017220517A1/en active Application Filing
- 2017-06-20 CN CN202210807089.7A patent/CN115093418A/en active Pending
- 2017-06-20 KR KR1020237014572A patent/KR20230062680A/en active IP Right Grant
- 2017-06-20 CN CN202111184338.3A patent/CN113943297A/en active Pending
- 2017-06-20 CN CN202210799583.3A patent/CN115073476A/en active Pending
- 2017-06-20 AU AU2017283136A patent/AU2017283136C1/en active Active
- 2017-06-20 MA MA045442A patent/MA45442A/en unknown
- 2017-06-20 EP EP22174808.0A patent/EP4108665A1/en active Pending
- 2017-06-20 RU RU2018146657A patent/RU2741597C2/en active
- 2017-06-20 EP EP17731149.5A patent/EP3475282B1/en active Active
- 2017-06-20 BR BR112018075143-0A patent/BR112018075143A2/en not_active Application Discontinuation
- 2017-06-20 PE PE2018003112A patent/PE20190109A1/en unknown
- 2017-06-20 KR KR1020187037004A patent/KR102530131B1/en active IP Right Grant
- 2017-06-20 JP JP2018566249A patent/JP6962942B2/en active Active
- 2017-06-20 CR CR20180615A patent/CR20180615A/en unknown
- 2017-06-20 MX MX2018014684A patent/MX2018014684A/en unknown
- 2017-06-20 CA CA3206921A patent/CA3206921A1/en active Pending
- 2017-06-20 SG SG11201809678VA patent/SG11201809678VA/en unknown
- 2017-06-20 CR CR20220661A patent/CR20220661A/en unknown
- 2017-06-20 CA CA3023043A patent/CA3023043A1/en active Pending
- 2017-06-21 AR ARP170101708A patent/AR108845A1/en unknown
- 2017-06-22 TW TW106120830A patent/TWI764908B/en active
- 2017-06-22 TW TW111101354A patent/TWI824380B/en active
-
2018
- 2018-10-19 CO CONC2018/0011231A patent/CO2018011231A2/en unknown
- 2018-10-25 ZA ZA2018/07133A patent/ZA201807133B/en unknown
- 2018-11-01 IL IL262711A patent/IL262711B2/en unknown
- 2018-12-14 CL CL2018003610A patent/CL2018003610A1/en unknown
- 2018-12-20 US US16/228,539 patent/US10457685B2/en active Active
- 2018-12-21 PH PH12018502733A patent/PH12018502733A1/en unknown
-
2021
- 2021-07-26 AU AU2021206925A patent/AU2021206925B2/en active Active
- 2021-10-14 JP JP2021168709A patent/JP7308246B2/en active Active
-
2022
- 2022-04-06 IL IL292015A patent/IL292015B2/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR108845A1 (en) | DERIVATIVES OF [1,2,3] TRIAZOLO [4,5-D] PYRIMIDINE AS MODULATORS OF THE CB2 RECEIVER | |
PE20190326A1 (en) | ISOQUINOLIN-3-IL-CARBOXAMIDES AND THE PREPARATION AND USE OF THEM | |
AR110405A1 (en) | COMPOUNDS | |
CR20160523A (en) | IMIDAZO COMPOUNDS [4,5-C] QUINOLIN-2-ONA AND ITS USE TO TREAT CANCER | |
AR078408A1 (en) | DERIVATIVES OF INDOL AS MODULATORS OF THE CRAC | |
PE20161405A1 (en) | CORTISTATIN ANALOGS AND SYNTHESIS AND USES OF THE SAME | |
PE20190656A1 (en) | TIAZOLO-PYRIDINE COMPOUNDS REPLACED AS INHIBITORS OF MALT1 | |
AR098912A1 (en) | SYK INHIBITORS | |
PE20171511A1 (en) | PIPERIDINE UREA 4-METHYLSULFONYL-SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF DILATED MYOCARDIOPATIA (DCM) | |
AR093937A1 (en) | CHEMICAL COMPOUNDS | |
AR093659A1 (en) | CYCLE DERIVATIVES OF NUCLEOSIDS AND USES OF THE SAME | |
CO6321261A2 (en) | HETEROCICLIC OR SIPROBICICLIC BICYCLIC DERIVATIVES LINKED PIRAZOLO [1,5-A] PYRIMIDINES PROCEDURES FOR THEIR PREPARATION AND USES OF THE SAME | |
EA201500875A1 (en) | DERIVATIVES OF THE STATE | |
AR100418A1 (en) | COMPOUNDS AND COMPOSITIONS TO INDUCE CONDROGENESIS | |
UY37774A (en) | SUBSTITUTED 5-CYANOINDOL COMPOUNDS AND USES OF THE SAME | |
PE20130401A1 (en) | HETEROARYL-CYCLOHEXYL-TETRAAZABENZO [E] BLUE | |
AR100714A1 (en) | 1-OXA-4,9-DIAZAESPIRO UNDECANO COMPOUND RENTAL AND ARYL DERIVATIVES THAT HAVE MULTIMODAL ACTIVITY AGAINST PAIN | |
PE20190339A1 (en) | 1H-PIRAZOLO [4,3-B] PYRIDINES AS INHIBITORS OF PDE1 | |
AR100713A1 (en) | AMIDA DERIVATIVES OF COMPOUNDS OF 1-OXA-4,9-DIAZAESPIRO UNDECENE THAT HAVE MULTIMODAL ACTIVITY AGAINST PAIN | |
AR071833A1 (en) | KINASE INHIBITORS (LIMK2), COMPOSITIONS THAT UNDERSTAND AND METHODS TO TREAT OR PREVENT DISEASES | |
AR085750A1 (en) | PYRAZOLO-PYRIMIDINE DERIVATIVES | |
AR101255A1 (en) | ISOINDOLINONE DERIVATIVES | |
AR111494A1 (en) | ANILINOQUINAZOLINE C₅ COMPOUNDS AND ITS USE IN CANCER TREATMENT | |
AR102544A1 (en) | COMPOUNDS DERIVED FROM DIHYDROHYDANTOINE AS HERBICIDES | |
BR112019001968A2 (en) | pyrazolo [1,5-a] pyrimidine compound |